Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 3, 2015, Pages 170-177

  Pan, Y ^a   Qiao, Q Y ^b   Pan, L H ^b   Zhou, D C ^b   Hu, C ^a   Gu, H F ^b   Fu, S K ^b   Liu, X L ^a   Jin, H M ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

adipocyte; insulin receptor; insulin resistance; losartan; oxidative stress

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; AMLODIPINE; GLUCOSE; HEMOGLOBIN A1C; HYDROGEN PEROXIDE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LOSARTAN; PHOSPHATIDYLINOSITOL 3 KINASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN; ANTIHYPERTENSIVE AGENT;

3T3 CELL LINE; ADIPOCYTE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY CONCENTRATING CAPACITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MOUSE; PHYSIOLOGY;

3T3-L1 CELLS; ADIPOCYTES; AGED; AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; HUMANS; INSULIN RESISTANCE; LOSARTAN; MALE; MICE; MIDDLE AGED; OXIDATIVE STRESS; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84925233105     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1395658     Document Type: Article

References (38)

1. Burns K. D. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis: 2000; 36 449 465
2. Satoh M., Fujimoto S., Haruna Y. et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol: 2005; 288 F1144 F1152
3. Gorin Y., Block K., Hernandez J. et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem: 2005; 280 39616 39626
4. Fujita H., Sakamoto T., Komatsu K. et al. Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res: 2011; 34 1302 1308
5. Booth G. L., Kapral M. K., Fung K. et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet: 2006; 368 29 36
6. Crutchlow M. F., Robinson B., Pappachen B. et al. Validation of steady-state insulin sensitivity indices in chronic kidney disease. Diabetes Care: 2007; 30 1813 1818
7. Engeli S., Gorzelniak K., Kreutz R. et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens: 1999; 17 555 560
8. Cassis L. A., Police S. B., Yiannikouris F. et al. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep: 2008; 10 93 98
9. Tian F., Luo R., Zhao Z. et al. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes: 2010; 118 258 265
10. Mor A., Aizman E., George J. et al. RAS inhibition induces insulin sensitivity and glucose uptake. PloS One: 2011; 6 e21712
11. Aksnes T. A., Flaa A., Sevre K. et al. Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade. Blood Press: 2008; 17 156 163
12. Furuhashi M., Ura N., Higashiura K. et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension: 2003; 42 76 81
13. Guo L. L., Pan Y., Jin H. M. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant: 2009; 24 1876 1883
14. Lee M. H., Song H. K., Ko G. J. et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int: 2008; 74 890 900
15. Furuhashi M., Ura N., Takizawa H. et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens: 2004; 22 1977 1982
16. Younis F., Stern N., Limor R. et al. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism: 2010; 59 1200 1209
17. Cole B. K., Keller S. R., Wu R. et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension: 2010; 55 715 721
18. Muñoz M. C., Giani J. F., Dominici F. P. et al. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens: 2009; 27 2409 2420
19. Bonora E., Targher G., Alberiche M. et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the Assessment of Insulin sensitivity. Diabetes Care: 2000; 23 57 63
20. Sakoda H., Ogihara T., Anai M. et al. Dexamethasone-induced insulin resistance in 3T3L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes: 2000; 49 1700 1708
21. Guo H., Ling W., Wang Q. et al. Cyanidin 3-glucoside protects 3T3-L1 adipocytes against H2O2- or TNF-alpha-induced insulin resistance by inhibiting c-Jun NH2-terminal kinase activation. Biochem Pharmacol: 2008; 75 1393 1401
22. Zou J., Li Y., Fan H. Q. et al. Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells. BMC Res Notes: 2012; 5 168
23. Wu L. L., Chiou C. C., Chang P. Y. et al. Urinary 8-OhdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta: 2004; 339 1 9
24. Son S. M. Reactive Oxygen and Nitrogen Species in Pathogenesis of Vascular Complications of Diabetes. Diabetes Metab J: 2012; 36 190 198
25. Fujita H., Fujishima H., Chida S. et al. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol: 2009; 20 1303 1313
26. Arozal W., Watanabe K., Veeraveedu P. T. et al. Effects of Angiotensin Receptor Blocker on Oxidative Stress and Cardio-Renal Function in Streptozotocin-Induced Diabetic Rats. Biol Pharm Bull: 2009; 32 1411 1416
27. Fan Q., Liao J., Kobayashi M. et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant: 2004; 19 3012 3020
28. Nakamura A., Shikata K., Nakatou T. et al. Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy. J Diabetes Investig: 2013; 4 195 201
29. Ogawa S., Kobori H., Ohashi N. et al. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic nephropathy. Biomark Insights: 2009; 4 97 102
30. Ogawa S., Mori T., Nako K. et al. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy. Hypertension: 2006; 47 699 705
31. Kayabasi H., Yilmaz Z., Sit D. et al. The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis. Eur Rev Med Pharmacol Sci: 2013; 17 235 242
32. Clasen R., Schupp M., Foryst-Ludwig A. et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension: 2005; 46 137 143
33. Watanabe S., Okura T., Kurata M. et al. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther: 2006; 28 1677 1685
34. Hotamisligil G. S., Arner P., Caro J. F. et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest: 1995; 95 2409 2415
35. Heydrick S. J., Gautier N., Olichon-Berthe C. et al. Early alteration of insulin stimulation of PI 3-kinase in muscle and adipocyte from gold thioglucose obese mice. Am J Physiol: 1995; 268 E604 E612
36. Tanti J. F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol: 2009; 9 753 762
37. Sevillano J., de Castro J., Bocos C. et al. Role of insulin receptor substrate-1 serine 307 phosphorylation and adiponectin in adipose tissue insulin resistance in late pregnancy. Endocrinology: 2007; 148 5933 5942
38. Maiuri T., Ho J., Stambolic V. Regulation of adipocyte differentiation by distinct subcellular pools of protein kinase B (PKB/Akt). J Biol Chem: 2010; 285 15038 15047